- Home
- RYAN vs CORT Comparison
RYAN vs CORT Comparison
Compare RYAN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RYAN | CORT |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 3.7B |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | RYAN | CORT |
|---|---|---|
| Price | $37.25 | $33.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | $56.50 | ★ $105.20 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 05-15-2026 | 05-25-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | ★ $3,051,126,000.00 | $761,407,000.00 |
| Revenue This Year | $18.15 | $29.97 |
| Revenue Next Year | $13.74 | $30.25 |
| P/E Ratio | $86.72 | ★ $41.48 |
| Revenue Growth | ★ 21.28 | 12.79 |
| 52 Week Low | $37.29 | $28.66 |
| 52 Week High | $77.00 | $117.33 |
Technical Indicators
Market Signals| Indicator | RYAN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 30.76 | 32.93 |
| Support Level | N/A | $28.66 |
| Resistance Level | $59.01 | $41.92 |
| Average True Range (ATR) | 1.55 | 2.41 |
| MACD | 0.20 | 0.23 |
| Stochastic Oscillator | 10.61 | 41.39 |
Price Performance
Historical ComparisonAbout RYAN Ryan Specialty Holdings Inc.
Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.